CD19 and Miyoshi myopathy: The generated CAR-NK-92 cells targeting CD19 and/or CD138 antigens that employ CD28, 4-1BB, and CD3ζ signaling displayed high and selective cytotoxicity against established leukemia, lymphoma, and MM cells in vitro.